verve therapeutics inc. - VERV
VERV
Close Chg Chg %
5.22 -0.65 -12.45%
Closed Market
4.57
-0.65 (12.45%)
Volume: 1.90M
Last Updated:
Mar 31, 2025, 4:00 PM EDT
Company Overview: verve therapeutics inc. - VERV
VERV Key Data
| Open $5.02 | Day Range 4.54 - 5.02 |
| 52 Week Range 4.31 - 13.24 | Market Cap $463.51M |
| Shares Outstanding 88.80M | Public Float 66.18M |
| Beta 1.78 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$2.35 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.25M |
VERV Performance
| 1 Week | -5.95% | ||
| 1 Month | -17.54% | ||
| 3 Months | -7.45% | ||
| 1 Year | -60.69% | ||
| 5 Years | N/A |
VERV Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
10
Full Ratings ➔
About verve therapeutics inc. - VERV
Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.
VERV At a Glance
Verve Therapeutics, Inc.
201 Brookline Avenue
Boston, Massachusetts 02215
| Phone | 1-617-603-0070 | Revenue | 32.33M | |
| Industry | Biotechnology | Net Income | -198,709,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 174.979% | |
| Fiscal Year-end | 12 / 2025 | Employees | 274 | |
| View SEC Filings |
VERV Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 14.779 |
| Price to Book Ratio | 1.015 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.106 |
| Enterprise Value to Sales | 0.728 |
| Total Debt to Enterprise Value | 2.973 |
VERV Efficiency
| Revenue/Employee | 118,000.00 |
| Income Per Employee | -725,215.328 |
| Receivables Turnover | 9.933 |
| Total Asset Turnover | 0.046 |
VERV Liquidity
| Current Ratio | 12.649 |
| Quick Ratio | 12.649 |
| Cash Ratio | 12.218 |
VERV Profitability
| Gross Margin | 79.114 |
| Operating Margin | -707.225 |
| Pretax Margin | -613.51 |
| Net Margin | -614.589 |
| Return on Assets | -28.385 |
| Return on Equity | -36.364 |
| Return on Total Capital | -35.271 |
| Return on Invested Capital | -32.651 |
VERV Capital Structure
| Total Debt to Total Equity | 14.184 |
| Total Debt to Total Capital | 12.422 |
| Total Debt to Total Assets | 10.81 |
| Long-Term Debt to Equity | 12.067 |
| Long-Term Debt to Total Capital | 10.568 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Verve Therapeutics Inc. - VERV
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | 1.94M | 11.76M | 32.33M | |
Sales Growth
| - | - | +505.77% | +174.98% | - |
Cost of Goods Sold (COGS) incl D&A
| 3.38M | 6.71M | 5.46M | 6.75M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 3.38M | 6.71M | 5.46M | 6.75M | |
Depreciation
| 3.38M | 6.71M | 5.46M | 6.75M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +154.29% | +98.73% | -18.72% | +23.79% | |
Gross Income
| (3.38M) | (4.77M) | 6.30M | 25.58M | |
Gross Income Growth
| -154.29% | -41.25% | +232.14% | +305.82% | |
Gross Profit Margin
| - | -245.75% | +53.61% | +79.11% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 83.69M | 160.92M | 229.43M | 254.24M | |
Research & Development
| 68.20M | 130.09M | 184.95M | 197.59M | |
Other SG&A
| 15.49M | 30.82M | 44.48M | 56.65M | |
SGA Growth
| +112.96% | +92.28% | +42.57% | +10.81% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 33.39M | (1.49M) | (165.00K) | (1.54M) | |
EBIT after Unusual Expense
| (120.46M) | (164.20M) | (222.96M) | (227.12M) | |
Non Operating Income/Expense
| 142.00K | 6.87M | 23.17M | 28.76M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (120.31M) | (157.33M) | (199.79M) | (198.36M) | |
Pretax Income Growth
| -163.25% | -30.77% | -26.99% | +0.72% | |
Pretax Margin
| - | -8,105.82% | -1,699.21% | -613.51% | |
Income Tax
| - | 53.00K | 275.00K | 349.00K | |
Income Tax - Current - Domestic
| - | - | 275.00K | 349.00K | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (120.31M) | (157.39M) | (200.07M) | (198.71M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (120.31M) | (157.39M) | (200.07M) | (198.71M) | |
Net Income Growth
| -163.25% | -30.81% | -27.12% | +0.68% | |
Net Margin Growth
| - | -8,108.55% | -1,701.55% | -614.59% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (120.31M) | (157.39M) | (200.07M) | (198.71M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (120.31M) | (157.39M) | (200.07M) | (198.71M) | |
EPS (Basic)
| -2.4801 | -2.9133 | -3.1175 | -2.3454 | |
EPS (Basic) Growth
| -161.64% | -17.47% | -7.01% | +24.77% | |
Basic Shares Outstanding
| 48.51M | 54.02M | 64.18M | 84.72M | |
EPS (Diluted)
| -2.4801 | -2.9133 | -3.1175 | -2.3454 | |
EPS (Diluted) Growth
| -161.64% | -17.47% | -7.01% | +24.77% | |
Diluted Shares Outstanding
| 48.51M | 54.02M | 64.18M | 84.72M | |
EBITDA
| (83.69M) | (158.98M) | (217.67M) | (221.91M) | |
EBITDA Growth
| -112.96% | -89.96% | -36.92% | -1.95% | |
EBITDA Margin
| - | -8,190.42% | -1,851.24% | -686.34% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 24.00 | |
| Number of Ratings | 10 | Current Quarters Estimate | -0.67 | |
| FY Report Date | 06 / 2025 | Current Year's Estimate | -2.667 | |
| Last Quarter’s Earnings | -0.65 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -2.35 | Next Fiscal Year Estimate | -2.69 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 10 | 10 | 10 | 9 |
| Mean Estimate | -0.67 | -0.68 | -2.67 | -2.69 |
| High Estimates | -0.52 | -0.52 | -2.02 | -2.17 |
| Low Estimate | -0.83 | -0.91 | -3.28 | -3.24 |
| Coefficient of Variance | -14.29 | -16.58 | -13.84 | -16.28 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 8 | 8 | 9 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 2 | 2 | 2 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Verve Therapeutics Inc. - VERV
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Verve Therapeutics Inc. - VERV
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 10, 2025 | Allison Dorval Chief Financial Officer | 258,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 10, 2025 | Jason Politi Chief Technical Ops. Off. | 225,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 10, 2025 | Jason Politi Chief Technical Ops. Off. | 40,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 10, 2025 | Sekar Kathiresan Chief Executive Officer; Director | 150,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 10, 2025 | Sekar Kathiresan Chief Executive Officer; Director | 120,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 10, 2025 | Sekar Kathiresan Chief Executive Officer; Director | 488,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 10, 2025 | Troy Lister Chief Scientific Officer | 40,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 10, 2025 | Troy Lister Chief Scientific Officer | 225,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 10, 2025 | Allison Dorval Chief Financial Officer | 75,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 10, 2025 | Allison Dorval Chief Financial Officer | 45,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 10, 2025 | Andrew D. Ashe See Remarks | 225,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 10, 2025 | Joan Nickerson Chief Administrative Officer | 40,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 10, 2025 | Joan Nickerson Chief Administrative Officer | 225,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 10, 2025 | Andrew D. Ashe See Remarks | 40,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 28, 2024 | Krishna Yeshwant Director | 136,139 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 28, 2024 | Jodie P. Morrison Director | 267,541 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 28, 2024 | Alexander Gery Cumbo Director | 136,139 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 28, 2024 | Sheila A. Mikhail Director | 136,139 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 28, 2024 | Michael F. MacLean Director | 136,139 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 28, 2024 | Lonnel Coats Director | 136,139 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |